Stevanato Group S.p.A. (STVN)
NYSE · Healthcare · Medical Instruments & Supplies
$20.05−0.74%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $5.5B
- P/E (trailing)
- 35.2
- Forward P/E
- 23.8
- Dividend yield
- 0.3%
- 52-week range
- $12.89 – $27.99
- 52-week change
- −17.65%
- EPS (trailing)
- $0.57
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 5, 2026
About Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers.
Headquarters: Piombino Dese, Italy · 6,010 employees · stevanatogroup.com